Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells

The mutant JAK2V617F tyrosine kinase (TK) is present in the majority of patients with BCR-ABL–negative myeloproliferative neoplasms (MPNs). JAK2V617F activates downstream signaling through the signal transducers and activators of transcription (STAT), RAS/mitogen-activated protein kinase (MAPK), and...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Wang, Yongchao, Fiskus, Warren, Chong, Daniel G., Buckley, Kathleen M., Natarajan, Kavita, Rao, Rekha, Joshi, Atul, Balusu, Ramesh, Koul, Sanjay, Chen, Jianguang, Savoie, Andrew, Ustun, Celalettin, Jillella, Anand P., Atadja, Peter, Levine, Ross L., Bhalla, Kapil N.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2009
Témata:
Myeloid Neoplasia
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2788976/
https://ncbi.nlm.nih.gov/pubmed/19828702
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-05-222133
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky